Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 06 - 23 save search
Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: -1.09%
disease alzheimer treatment fda therapy antibody breakthrough therapy alzheimer’s alzheimer's disease alzheimer's designation lecanemab anti-amyloid beta
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
Published: 2021-06-23 (Crawled : 21:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -0.81%
H: 2.24%
C: 1.02%
treatment solid tumors ongoing phase 1 trial phase 2 keytruda
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
Published: 2021-06-23 (Crawled : 18:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.59%
H: 0.29%
C: -0.1%
treatment migraine injection
Dutch Biotech Acquires Corlieve to Develop Treatment for Temporal Lobe Epilepsy
Published: 2021-06-23 (Crawled : 17:00) - biospace.com/
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: 0.52%
H: 1.49%
C: 0.5%
treatment biotech iot
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
Published: 2021-06-23 (Crawled : 13:15) - globenewswire.com
YMAB | $15.26 -0.52% -0.52% 160K
|
Health Technology
|
| O: -1.41%
H: 3.88%
C: 2.06%
treatment
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
Published: 2021-06-23 (Crawled : 13:00) - globenewswire.com
XBIT | $8.075 -1.28% -1.3% 65K
|
Health Technology
|
| O: -0.12%
H: 1.73%
C: 1.17%
treatment cancer biotech iot trial pancreatic pancreas enroll
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
Published: 2021-06-23 (Crawled : 12:15) - globenewswire.com
COCP | $1.562 -1.39% 3.9K
|
Health Technology
|
| O: 0.0%
H: 2.67%
C: 2.29%
treatment phase 1 influenza trial cc-42344
New ReTo Project to Conduct Annual Iron Ore Tailings Treatment with Capacity of Three Million Tons and Anticipated Sales of Approximately RMB 280 Million
Published: 2021-06-23 (Crawled : 12:00) - prnewswire.com
RETO | $0.93 4.35% 25K
|
Non-Energy Minerals
|
| O: 20.51%
H: 20.57%
C: -6.38%
sales treatment
aTyr Pharma to Host Virtual Key Opinion Leader Event on Current Treatment Options for Pulmonary Sarcoidosis
Published: 2021-06-23 (Crawled : 12:00) - globenewswire.com
LIFE | $1.595 -1.54% -1.57% 290K
|
Health Technology
|
| O: -0.9%
H: 3.88%
C: 3.2%
treatment pharma
Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.59%
H: 0.02%
C: -1.01%
disease treatment clinical trials trial rare
Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
EDIT | News | $5.355 -1.92% -1.96% 1.6M
|
Health Technology
|
| O: 0.0%
H: 5.03%
C: 3.87%
treatment trial enroll
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Published: 2021-06-23 (Crawled : 12:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: 1.32%
H: 4.07%
C: -2.12%
treatment positive nash liver
Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
Published: 2021-06-23 (Crawled : 02:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.34%
H: 0.02%
C: -2.29%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.48%
H: 0.29%
C: -0.43%
treatment therapy phase 3 cell carcinoma
Energy-based Non-invasive Medical Aesthetic Treatment System Market to reach $ 1.29 billion|Technavio
Published: 2021-06-23 (Crawled : 02:00) - prnewswire.com
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -0.58%
treatment energy aesthetic
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.